Alexandros Rentzos

Interventional Neuroradiologist, Neurointerventional unit, Sahlgrenska University Hospital.

[Stroke AHA/ASA @StrokeAHA_ASA]

#STROKE: Simultaneous publication at #ESOC2026 🔴🔵: Unsuccessful recanalization occurs in ~30% of all EVT cases, and it remains highly challenging to predict which patients will experience it. EVT should still be offered to all eligible patients. https://t.co/yH9in3OjOI

[Johanna Seiden, MD MPH @JohannaSeidenMD]

MeVO Trials 2.0 @neurona_critica
#ISC26 @StrokeAHA_ASA
@caseyalbin @SposatoL @rkchoi @JimmySuhMD @JayDoliaMD @SitaraKoneru @gdawod1 @JenHarrisMD
@bustinclots247 @ShadiYaghi2 @AlexandraCzap
@a_charidimou @JimSiegler @svinsociety @BraydonDymm @Braindoc_MGH @rwregen @NguyenThanhMD

[Johanna Seiden, MD MPH @JohannaSeidenMD]

#ISC26 @StrokeAHA_ASA
ORIENTAL-MeVO: A positive trial in MeVO space shows that EVT within 24 hrs of sx onset among pts with moderate/high clinical severity improved 90-day functional outcomes without increasing mortality or sICH @RaulNogueiraMD

[Ingrid Marques @marquesingrid12]

📚CHOICE II #ISC26
✅️ IA Alteplase following successful thrombectomy
✅️ Increases the rates of excellent functional outcomes
✅️ Reduces persistent hypoperfusion
✅️ Does not increase the risks of sICH

[AHA Science @AHAScience]

CHOICE2 results presented at #ISC26

[Eytan Raz @eytanraz]

Our @TheJNS paper is out: In perimesencephalic SAH, high-res CBCT frequently identifies a basilar perforator pseudoaneurysm supporting an arterial etiology until proven otherwise. Conservative management was associated with excellent outcomes. https://t.co/eL5vELrIKA

[Ayrton Massaro @AyrtonMassaro]

#ISC26 CHOICE 2 TRIAL - IA alteplase following successful thrombectomy increases the rates of excellent function outcome, reduces the rate of persistent hypoperfusion without increasing risk of ICH.

[Stroke AHA/ASA @StrokeAHA_ASA]

In an observational cohort study, unwitnessed patients with LVO undergoing EVT had at least the same likelihood of favorable outcomes as witnessed patients when presenting in the extended time window. https://t.co/vsT1TsUEKK

@PrCCordonnier @NguyenThanhMD @NagelSimon @shadiyaghi2

[Muhammad Aemaz Ur Rehman @aemaz100]

Landmark CREST-2 trial just released at #SVIN25. The trial is positive!! Benefit of CAS+MM over MM alone in asymptomatic high grade carotid stenosis. More importantly, no benefit seen for CEA+MM compared to MM alone.

Exciting times ahead!

[NEJM @NEJM]

Presented at #SVIN25:

CREST-2: In high-grade asymptomatic carotid stenosis, addition of stenting to medical therapy led to a lower risk of stroke over a 4-year period. Endarterectomy did not lead to a significant benefit. Full results: https://t.co/ojge1CjqiU

Editorial: Managing Asymptomatic Carotid Stenosis https://t.co/D9LH89Edyk

@svinsociety

[NEJM @NEJM]

Original Article: Medical Management and Revascularization for Asymptomatic Carotid Stenosis (CREST-2) https://t.co/ZHLCV9ukNU

Editorial: Managing Asymptomatic Carotid Stenosis https://t.co/dLgi1iv8v0

#SVIN25 | @svinsociety

[Stroke AHA/ASA @StrokeAHA_ASA]

#Stroke InterSECT by @DotunOlalusi et al.: To tackle strokophobia, stroke education should be tailored to improve confidence and clinical outcome. https://t.co/WaipdkJpC8

[Stroke AHA/ASA @StrokeAHA_ASA]

In a systematic review and study-level meta-analysis, TNK improved excellent functional outcomes and recanalization in AIS patients treated within 4.5-24 hours, without increasing the risks of sICH or mortality. #stroke https://t.co/6m34Pm2pyJ

[AHA Science @AHAScience]

🧵/ Late breaking science results from #ISC25 will be posted to this thread at the time of presentation.

(bookmark this post)

DISTAL
ESCAPE-MeVO
DISCOUNT
TRANSPORT2
C3FIT
PRESTIGE-AF
ANGEL-TNK
HOPE

[NEJM @NEJM]

Patients with evidence of microplastics and nanoplastics in carotid artery plaque, as compared with patients without, had a greater risk of adverse cardiovascular events at 34 months of follow-up. Read the full article: https://t.co/BUsdzHMcdb

[Eytan Raz @eytanraz]

I am following #ISC2024 online, will update everyone here on results of MMA Subdural Embo trials. Starting shortly.

[Fawaz Al-Mufti, MD, FSVIN @almuftifawaz]

EMBOLISE Trial: Surgical Cohort results announced at #ISC24

MMA embolization with Onyx led to a 3-fold reduction in recurrences requiring surgical drainage compared to
Surgery Alone - per CEC adjudication (4.1% vs 11.3%, p=0.0081).

NNT14!

#ISC24

[Jens Fiehler @Fie0815]

Another big win: EMBOLISE RCT shows superiority of MMA embolisation in reducing cSDH recurrence/retreament ‼️ Substantial effect size observed. @_AdnanSiddiqui @Medtronic_NV @JMDaviesMDPhD #ISC24 @esmintsociety @ESOstroke @DGNR_org

[AHA Science @AHAScience]

MAGIC-MT results presented at #ISC24

[Fawaz Al-Mufti, MD, FSVIN @almuftifawaz]

STEM Trial: SQUID
for Treatment of Chronic Subdural Hematoma presented by @AdamArthurMD at #ISC24

310 Patients randomized.

1⁰ Endpoint
Re-accumulation of the SDH on 180-day: 39.29 vs 15.2% favoring MMA embolization.
OR 3.60(1.91-6.78) p=0.0001

The future is bright.